- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Edward W. Cowen Addresses Current Management of Pustular Psoriasis
Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses treatment considerations for patients with different types of pustular psoriasis.
With no currently established standard of care for pustular psoriasis, treatment considerations depend on the extent and type of disease present in patients, said Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health.
Transcript
Can you speak on the current standard of care for pustular psoriasis, including screening and treatment?
There really is not a specific standard of care based on current National Psoriasis Foundation guidelines for pustular psoriasis. Treatment does need to be tailored to the patient and will be determined by the extent of their disease, and whether or not they have systemic symptoms.
Many patients may have localized disease, which might be controllable with just aggressive topical therapy. However, other patients with difficult-to-control disease or with generalized disease will often require systemic treatment. So, this could include immunosuppressive therapies like cyclosporine or methotrexate, systemic retinoids like acitretin, or often some of the newer biologic therapies.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
